Dr. Swapnil Sharma
@(banasthali.ac.in
Associate Professor, Department of Pharmacy
Banasthali Vidyapith
RESEARCH INTERESTS
Basic and Experimental Pharmacology
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Shivangi Jaiswal, Kanika Verma, Jaya Dwivedi, and Swapnil Sharma
Elsevier BV
Viral infections represent a significant threat to global health due to their highly communicable and potentially lethal nature. Conventional antiviral interventions encounter challenges such as drug resistance, tolerability issues, specificity concerns, high costs, side effects, and the constant mutation of viral proteins. Consequently, the exploration of alternative approaches is imperative. Therefore, nanotechnology-embedded drugs excelled as a novel approach purporting severe life-threatening viral disease. Integrating nanomaterials and nanoparticles enables ensuring precise drug targeting, improved drug delivery, and fostered pharmacokinetic properties. Notably, nanocrystals (NCs) stand out as one of the most promising nanoformulations, offering remarkable characteristics in terms of physicochemical properties (higher drug loading, improved solubility, and drug retention), pharmacokinetics (enhanced bioavailability, dose reduction), and optical properties (light absorptivity, photoluminescence). These attributes make NCs effective in diagnosing and ameliorating viral infections. This review comprises the prevalence, pathophysiology, and resistance of viral infections along with emphasizing on failure of current antivirals in the management of the diseases. Moreover, the review also highlights the role of NCs in various viral infections in mitigating, diagnosing, and other NC-based strategies combating viral infections. In vitro, in vivo, and clinical studies evident for the effectiveness of NCs against viral pathogens are also discussed.
Saraswati Patel, Sonika Jain, Ritika Gururani, Swapnil Sharma, and Jaya Dwivedi
Springer Science and Business Media LLC
Neetu Yaduvanshi, Sanjana Tewari, Shivangi Jaiswal, Meenu Devi, Shruti Shukla, Jaya Dwivedi, and Swapnil Sharma
Elsevier BV
Priyanka Joshi, Saraswati Patel, Ajita Paliwal, Smita Jain, Kanika Verma, Jaya Dwivedi, and Swapnil Sharma
Elsevier BV
Kirtika Madan, Sarvesh Paliwal, Swapnil Sharma, Seema Kesar, Neha Chauhan, and Mansi Madan
Bentham Science Publishers Ltd.
Background: Metabolic syndrome is one of the major non-communicable global health hazards of the modern world owing to its amplifying prevalence. Acetyl coenzyme-A carboxylase 2 (ACC 2) is one of the most crucial enzymes involved in the manifestation of this disease because of its regulatory role in fatty acid metabolism. Objective: To find novel potent ACC 2 inhibitors as therapeutic potential leads for combating metabolic syndrome. Methods: In the present study, a two-dimensional quantitative structure-activity relationship (2D QSAR) approach was executed on biologically relevant thiazolyl phenyl ether derivatives as ACC 2 inhibitors for structural optimization. The physiochemical descriptors were calculated and thus a correlation was derived between the observed and predicted activity by the regression equation. The significant descriptors i.e. log P (Whole Molecule) and Number of H-bond Donors (Substituent 1) obtained under study were considered for the design of new compounds and their predicted biological activity was calculated from the regression equation of the developed model. The compounds were further validated by docking studies with the prepared ACC 2 receptor. Results: The most promising predicted leads with the absence of an H-bond donor group at the substituted phenyl ether moiety yet increased overall lipophilicity exhibited excellent amino acid binding affinity with the receptor and showed predicted inhibitory activity of 0.0025 µM and 0.0027 µM. The newly designed compounds were checked for their novelty. Lipinski's rule of five was applied to check their druggability and no violation of this rule was observed. Conclusion: The compounds designed in the present study have tremendous potential to yield orally active ACC 2 inhibitors to treat metabolic syndrome.
Shivangi Jaiswal, Jaya Dwivedi, Dharma Kishore, and Swapnil Sharma
Bentham Science Publishers Ltd.
Abstract: Tetrazole is a most versatile pharmacophore of which more than twenty FDAapproved drugs have been marketed globally for the management of various diseases. In spite of many remarkable and consistent efforts having been made by the chemists towards the development of greener and sustainable strategies for the synthesis of tetrazole derivatives, this approach still needs more attention. The present review focuses on the green synthetic approach for the preparation of tetrazole derivatives from different starting materials such as nitrile, isonitrile, carbonyl, amine, amide, oxime and terminal alkyne functions. The mechanism of tetrazole synthesis from different substrates is discussed. In addition to this, a four component Ugi-azide reaction to the tetrazole synthesis is also described. Of note, the present articles exploited several water-mediated and solvent-free methodologies for tetrazole synthesis. The important key features of tetrazole synthesis were pinpointing in each synthetic scheme which provides excellent guide to those searching for selective procedure to achieve the desired transformation. This review seeks to present a timely account (2011-2023) on the splendid array of ecofriendly procedures of synthesis known today for the preparation of tetrazole derivatives from different starting materials. The rational of this review is to enlighten recent advancements in the synthesis of tetrazole derivatives from different substrates.
Ajita Paliwal, Vartika Paliwal, Smita Jain, Sarvesh Paliwal, and Swapnil Sharma
Bentham Science Publishers Ltd.
Abstract: The glucokinase regulator (GCKR) gene encodes an inhibitor of the glucokinase enzyme (GCK), found only in hepatocytes and responsible for glucose metabolism. A common GCKR coding variation has been linked to various metabolic traits in genome-wide association studies. Rare GCKR polymorphisms influence GKRP activity, expression, and localization. Despite not being the cause, these variations are linked to hypertriglyceridemia. Because of their crystal structures, we now better understand the molecular interactions between GKRP and the GCK. Finally, small molecules that specifically bind to GKRP and decrease blood sugar levels in diabetic models have been identified. GCKR allelic spectrum changes affect lipid and glucose homeostasis. GKRP dysfunction has been linked to a variety of molecular causes, according to functional analysis. Numerous studies have shown that GKRP dysfunction is not the only cause of hypertriglyceridemia, implying that type 2 diabetes could be treated by activating liver-specific GCK via small molecule GKRP inhibition. The review emphasizes current discoveries concerning the characteristic roles of glucokinase and GKRP in hepatic glucose metabolism and diabetes. This information has influenced the growth of directed molecular therapies for diabetes, which has improved our understanding of lipid and glucose physiology.
Smita Jain, Swapnil Sharma, Ajita Paliwal, Jaya Dwivedi, Shailendra Paliwal, Vartika Paliwal, Sarvesh Paliwal, and Jaiprakash Sharma
Springer Science and Business Media LLC
Sarvesh Paliwal, Jaiprakash Sharma, Vivek Dave, Swapnil Sharma, Kanika Verma, Kajal Tak, Raghava Reddy Kakarla, Veera Sadhu, Pavan Walvekar, and Tejraj M. Aminabhavi
Springer Science and Business Media LLC
The novel coronavirus disease (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), affected millions of people worldwide at an alarming rate. Moreover, the development of vaccines is still hope, but its camouflage mutations during transmission are still a challenge. In the dire condition of this pandemic, drug repurposing with the exploitation of computational modeling has become the cynosure to repurpose the already existing drugs such as remdesivir, Favipiravir, dexamethasone, and other drugs at clinical levels. Furthermore, their safety and efficacy against COVID-19 remain a challenge in different age groups and populations with pre-existing conditions like heart disease, hepatic and renal impairment, pregnancy, and immunocompromised states. Moreover, computational modeling allows studying physiological and biochemical parameters on drug transport, delivery, and therapeutic efficacy of dosage forms. This review explicitly provides a comprehensive account of the challenges and opportunities for developing physiologically based pharmacokinetic models (PBPK) and pharmacodynamic(PD) models to establish a therapeutic dosage regimen based on dose selection, safety, and efficacy. We also highlight the pharmacologic targeting strategies for ACE receptors, toxicity concerns, combination therapy, and drug-drug interactions for different repurposed drugs against COVID-19. In dreadful scenarios, PBPK and PD models hold promise for human PK and dose prediction in COVID-19, along with paving new horizons to improve the therapeutic as well as immuno-therapeutic efficacy using nano-drug delivery approaches, computer-aided drug design (CADD), and speed up clinical trials with a better understanding of quantitative in vitro to in vivo extrapolation (QIVIE) and established PK data.
Shivangi Jaiswal, Nikhilesh Arya, Neetu Yaduvanshi, Meenu Devi, Sonika Jain, Smita Jain, Jaya Dwivedi, and Swapnil Sharma
Elsevier BV
Neetu Yaduvanshi, Meenu Devi, Sanjana Tewari, Shivangi Jaiswal, Sonia Zeba Hashmi, Shruti Shukla, Jaya Dwivedi, and Swapnil Sharma
Elsevier BV
Priyanka Joshi, Kanika Verma, Deepak Kumar Semwal, Jaya Dwivedi, and Swapnil Sharma
Wiley
AbstractCancer is the world's second leading cause of mortality and one of the major public health problems. Cancer incidence and mortality rates remain high despite the great advancements in existing therapeutic, diagnostic, and preventive approaches. Therefore, a quest for less toxic and more efficient anti‐cancer strategies is still at the forefront of the current research. Traditionally important, curcumin commonly known as a wonder molecule has received considerable attention as an anti‐cancer, anti‐inflammatory, and antioxidant candidate. However, limited water solubility and low bioavailability restrict its extensive utility in different pathological states. The investigators are making consistent efforts to develop newer strategies to overcome its limitations by designing different analogues with better pharmacokinetic and pharmacodynamic properties. The present review highlights the recent updates on curcumin and its analogues with special emphasis on various mechanistic pathways involved in anti‐cancer activity. In addition, the structure–activity relationship of curcumin analogues has also been precisely discussed. This article will also provide key information for the design and development of newer curcumin analogues with desired pharmacokinetic and pharmacodynamic profiles and will provide in depth understanding of molecular pathways involved in the anti‐cancer activities.
Ritika Gururani, Saraswati Patel, Akansha Bisht, Smita Jain, Sarvesh Paliwal, Jaya Dwivedi, and Swapnil Sharma
Wiley
BACKGROUND
Tylophora indica (Burm. f.) Merr is a climbing perennial plant reported in Indian traditional system of medicine for its use in allergy and asthma. However, only few scientific studies have been performed in the past to validate its antiasthmatic potential.
OBJECTIVES
The present study deals with investigation of airway smooth muscle relaxant and antiasthmatic potential of extract and subsequent fractions prepared from T. indica.
METHODS
The most active fraction of T. indica leaves selected through bio-guided activity was subjected to liquid chromatography-mass spectrometry (LC-MS) analysis for chemical profiling. The binding affinity of identified compounds in fraction towards M3 and H1 receptors was determined by molecular docking study. F-2 (chloroform fraction prepared from methanolic extract of T. indica leaves) was examined for its smooth muscle relaxant properties using isolated trachea of guinea-pig. Further, F-2 was evaluated through in vivo studies employing ovalbumin-induced asthma model in guinea-pigs.
RESULTS
F-2 was found most effective in bioassay-guided fractionation. Characterization by LC-MS analysis revealed presence of five major bioactive compounds in F-2 that showed good docking interactions with M3 and H1 receptors. The ex vivo study demonstrated that F-2 could significantly relax tracheal rings via targeting multiple signalling pathways videlicet, namely, noncompetitive antagonism of the histamine and muscarinic receptors, β2-adrenergic stimulation and activation of soluble guanylyl cyclase. In in vivo studies, F-2 ameliorated airway hyperresponsiveness and decreased broncho alveolar lavage fluid (BALF) levels of inflammatory cytokines and immunoglobulin E (IgE).
CONCLUSION
These results confirm the traditional use of T. indica as an antiasthmatic agent which are evidenced through ex vivo, in silico and in vivo studies.
Jigar Panchal, Shivangi Jaiswal, Sonika Jain, Jyoti Kumawat, Ashima Sharma, Pankaj Jain, Smita Jain, Kanika Verma, Jaya Dwivedi, and Swapnil Sharma
Elsevier BV
Sonali Labhade, Smita Jain, Sohan Chitlange, Sarvesh Paliwal, and Swapnil Sharma
Elsevier BV
Payal Kesharwani, Akansha Bisht, Mayank Handa, Rahul Shukla, Mahendra Kumar Kesari, Shailendra Paliwal, Sarvesh Paliwal, and Swapnil Sharma
Elsevier BV
Swati Paliwal, Smita Jain, Pallavi Mudgal, Kanika Verma, Sarvesh Paliwal, and Swapnil Sharma
Elsevier BV
Priyanka Joshi, Akansha Bisht, Ajita Paliwal, Jaya Dwivedi, and Swapnil Sharma
Wiley
AbstractCurcumin, a natural polyphenol, derived from Curcuma longa L. is extensively studied by various researchers across the globe and has established its immense potential in the management of several disorders at clinical level. The underlying mechanism of curcumin involves regulation of various molecular targets, namely, inflammatory cytokines, transcription factor, apoptotic genes, growth factors, oxidative stress biomarkers, and protein kinases. In clinical trials, curcumin as an adjuvant has significantly boost‐up the efficacy of many proven drugs in the management of arthritis, neurodegenerative disorder, oral infection, and gastrointestinal disorders. Moreover, clinical studies have suggested curcumin as an appropriate candidate for the prevention and/or management of various cancers via regulation of signaling molecules including NF‐kB, cytokines, C‐reactive protein, prostaglandin E2, Nrf2, HO‐1, ALT, AST, kinases, and blood profiles. This article highlights plethora of clinical trials that have been conducted on curcumin and its derivatives in the management of several ailments. Besides, it provides recent updates to the investigators for conducting future research to fulfill the current gaps to expedite the curcumin utility in clinical subjects bearing different pathological states.
Akansha Bisht, Shruti Richa, Shivangi Jaiswal, Jaya Dwivedi, and Swapnil Sharma
CRC Press
Kanika Verma, Akanksha Chaturvedi, Swapnil Sharma, and Sunil Kumar Dubey
CRC Press
Meenu Devi, Shivangi Jaiswal, Neetu Yaduvanshi, Sonika Jain, Smita Jain, Kanika Verma, Rahul Verma, Dharma Kishore, Jaya Dwivedi, and Swapnil Sharma
Elsevier BV
Kanika Verma, Ritika Jaiswal, Sarvesh Paliwal, Jaya Dwivedi, and Swapnil Sharma
Wiley
Akt, a known serine/threonine‐protein kinase B has been revealed to be an imperative protein of the PI3K/Akt pathway. Akt is available in three isoforms, Akt1, Akt2, and Akt3. Ubiquitously expressed Akt1 & Akt2 are essential for cell survival and are believed to be involved in regulating glucose homeostasis. PI3K/Akt pathway has been evidenced to be associated with metabolic diseases viz. hypertension, dyslipidemia, and diabetes. Akt interacting proteins have been revealed to be scaffold proteins of the PI3K/Akt pathway. Notably, some protein–protein interactions are imperative for the inhibition or uncontrolled activation of these signaling pathways. For instance, Akt interacting protein binds with other protein namely, FOXO1 and mTOR, and play a key role in the onset and progression of metabolic syndrome (MS). The purpose of this review is to highlight the role of the PI3K/Akt pathway and associated protein–protein interactions which might serve as a valuable tool for investigators to develop some new promising therapeutic agents in the management of MS.
Kanika Verma, Rahul Shukla, Jaya Dwivedi, Sarvesh Paliwal, and Swapnil Sharma
Springer Science and Business Media LLC